Clinical Trial

AI-Guided Intensified Follow-up After Surgery for Acute Type A Aortic Dissection

Study acronym: AIMS-ATAAD-FU
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This multicenter, prospective, randomized controlled trial will evaluate whether an artificial intelligence (AI) multimodal prediction model-guided intensified follow-up strategy improves 1-year outcomes after surgery for acute Stanford type A aortic dissection. Eligible adult patients who have undergone open surgical repair or open plus endovascular/hybrid repair and are clinically stable to enter the postoperative follow-up phase will be randomized 1:1 to usual postoperative follow-up or AI-guided intensified follow-up. The AI-guided arm will receive usual follow-up plus an AI-generated risk stratification report for 1-year mortality and adverse aortic remodeling. Higher-risk patients may receive more frequent follow-up, prioritized CTA review, multidisciplinary assessment, and targeted management reminders. The primary outcome is all-cause mortality through postoperative day 365. Key secondary outcomes include aortic reintervention, adverse aortic remodeling, and ICU readmission within 1 year.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07623213
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: The Affiliated Hospital of Qingdao University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Guangdong Provincial People's Hospital, Sir Run Run Shaw Hospital, Wuhan Asia Heart Hospital, Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Beijing Anzhen Hospital
Conditions Acute Type A Aortic Dissection, Stanford Type A Aortic Dissection, Postoperative Aortic Dissection Follow-up
Enrollment 1,314 participants
Start Date 2026-12-01
Primary Completion 2028-12-01 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-03